Your browser is no longer supported. Please, upgrade your browser.
DNLI Denali Therapeutics Inc. daily Stock Chart
Denali Therapeutics Inc.
Index- P/E12.95 EPS (ttm)1.09 Insider Own9.36% Shs Outstand97.12M Perf Week-9.18%
Market Cap1.36B Forward P/E- EPS next Y-1.34 Insider Trans- Shs Float74.63M Perf Month-21.51%
Income-90.50M PEG- EPS next Q-0.20 Inst Own76.30% Short Float8.79% Perf Quarter-24.54%
Sales0.60M P/S2274.23 EPS this Y4.10% Inst Trans0.06% Short Ratio21.14 Perf Half Y-18.12%
Book/sh6.02 P/B2.33 EPS next Y-114.30% ROA- Target Price24.75 Perf Year-
Cash/sh3.84 P/C3.65 EPS next 5Y- ROE- 52W Range14.45 - 25.79 Perf YTD-10.17%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-45.52% Beta-
Dividend %- Quick Ratio22.00 Sales past 5Y- Gross Margin- 52W Low-2.77% ATR0.89
Employees130 Current Ratio22.00 Sales Q/Q- Oper. Margin- RSI (14)30.64 Volatility4.24% 4.92%
OptionableYes Debt/Eq0.00 EPS Q/Q88.80% Profit Margin- Rel Volume0.80 Prev Close14.49
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume310.20K Price14.05
Recom2.50 SMA20-13.31% SMA50-22.40% SMA200-26.97% Volume246,717 Change-3.04%
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Jan-02-18Initiated Morgan Stanley Overweight
Jan-02-18Initiated JP Morgan Overweight $24
Jan-02-18Initiated Goldman Neutral $19
Jan-02-18Initiated Evercore ISI Outperform $23
May-30-18 04:05PM  Denali Therapeutics Announces Early Exercise of Its Option to Acquire F-star Gamma GlobeNewswire
May-21-18 08:52AM  'Bursting at the seams,' this high-profile Peninsula biotech company is moving to a bigger home American City Business Journals
May-18-18 07:07PM  [$$] Life Sciences Investor Biomatics Capital Seeks $300 Million Second Fund The Wall Street Journal
May-11-18 08:00AM  Denali Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire -5.17%
Apr-05-18 08:53AM  Why Denali Therapeutics (DNLI) Could Shock the Market Soon Zacks
Mar-20-18 11:12AM  Here's When You Can Buy Twitter's Stock
10:48AM  Overall Market Action Is Preventing Aggressive Buying
Mar-19-18 08:00AM  Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights GlobeNewswire
Feb-08-18 09:00AM  Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines GlobeNewswire
Jan-05-18 07:00AM  Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases Business Wire
Jan-04-18 01:42PM  Snow, Skiing, And A Biotech VC's Outlook For 2018 Forbes
Jan-03-18 11:01AM  Analyst: Denali Therapeutics' Neuroscience Work Could Lead To Near-Term Upside Benzinga
Jan-02-18 12:03PM  3 Key Questions For Denali Therapeutics Investors Benzinga
Dec-28-17 05:14PM  Redwood City biopharma startup hopes to raise up to $98M in what could be Bay Area's first IPO of 2018 American City Business Journals -5.11%
Dec-20-17 05:50PM  Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinsons Disease GlobeNewswire
Dec-12-17 04:10PM  Denali Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-11-17 08:57AM  Bitcoin shorts face massive losses if Winklevosss call hits the mark MarketWatch
Dec-08-17 02:21PM  Nasdaq Welcomes Denali Therapeutics, Inc. (NASDAQ: DNLI) to The Nasdaq Stock Market GlobeNewswire
12:00PM  Denali Therapeutics Enters the Market With a Bang 24/7 Wall St.
11:21AM  Biotech Denali Therapeutics shares surge more than 20% in trading debut MarketWatch
08:37AM  Denali Therapeutics prices IPO at $18 a share, midpoint of price range MarketWatch
06:00AM  Denali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO GlobeNewswire
Dec-07-17 07:08PM  Denali Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
05:54PM  [$$] Quanterix Continues String of Life Sciences IPOs The Wall Street Journal
11:25AM  Denali Therapeutics upsizes IPO, to raise $250 million at midpoint of price range MarketWatch
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for the treatment of Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program that targets aSyn, a protein that has been identified as genetically linked to Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: beta-secretase 1/Tau, a bispecific program targeting the production of amyloid beta and the spreading of Tau. Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS. Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., as well as F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, and F-star Biotechnology Limited. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.